In what others are saying is a highly competitive market (which...

In what others are saying is a highly competitive market (which market isn't?) revenue growth of $8.1m was generated in the 2nd quarter against 1st quarter revenue of $4.5m.
2nd quarter FY2025 revenue of $8.1m vs $2.6m (pcp) 2nd quarter FY2024.
I am not discounting what other more experienced and 'hardened' investors in this segment have to say - be that good or bad for the future prospects of this company - but there is an obvious disparity between the challenges of some other companies in the sector and the rapidly accelerating growth of BXN.
The share price rose on the announcement 28th Jan and it will be interesting when the half year results are released on 28th Feb.

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDED 31 DECEMBER 2024 Highlights
 $8.1 million Q2 Revenue, up 77% on Q1 and an 310% increase on Q2 FY2024
 $12.6 million revenue H1 FY 2025 , up 267% on previous half
 Positive operating cash flow for the Quarter of $1.5 million from cash receipts of $7.4million.
 Cash on hand at 31 December 2024 at $2.7 million
 Increased manufacturing capacity to be commissioned in February 2025 will meetfurther growing production demand
 Regulatory approvals to be received shortly allowing export to UK
 Planning underway for proposed GMP manufacturing facility in Europe to meet localdemand